Search results for "Small Intestine"

showing 4 items of 94 documents

Eine Mannitollösung als orales Kontrastmittel in der pelvinen MRT

1995

PURPOSE Improvement of pelvic MRI using peroral administration of an aqueous mannitol solution. METHODS We retrospectively evaluated magnetic resonance examinations of 72 patients with suspected or proven pelvic abnormalities: In 36 patients, no bowel marking was carried out. In further 36 patients, we performed a contrast enhancement of the bowel by oral application of 1000 ml of an aqueous mannitol solution. RESULTS 8/36 (22%) patients suffered from diarrhoea, nausea or meteorism as a result of mannitol application. In group 2, an excellent bowel marking of the small intestine could be obtained in 36/36 (100%) patients. Contrast enhancement of the bowel significantly improved delineation …

medicine.medical_specialtyPelvic MRIContrast enhancementmedicine.diagnostic_testbusiness.industryNauseadigestive oral and skin physiologyMagnetic resonance imagingSmall intestineSurgerymedicine.anatomical_structureOral administrationmedicineRadiology Nuclear Medicine and imagingMannitolmedicine.symptombusinessNuclear medicineMannitol solutionmedicine.drugRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

CD36 Displays Features of a Lipid-Sensor Involved in Chylomicron Processing in the Rodent Small Intestine

2010

International audience; The membrane glycoprotein CD36 binds nanomolar concentrations of long-chain fatty acids (LCFA) and is highly expressed on the luminal surface of enterocytes. CD36 deficiency reduces chylomicron production through unknown mechanisms.In this report, we provide novel insights into the potential underlying mechanisms. Our in vivo data demonstrated that CD36 gene deletion in mice did not affect LCFA uptake and their subsequent esterification into triglycerides by the intestinal mucosa at micellar LCFA concentrations prevailing in the intestine. In rodents, CD36 protein early disappeared from the luminal side of intestinal villi during the post-prandial period but only whe…

medicine.medical_specialtyRodent030309 nutrition & dietetics[SDV]Life Sciences [q-bio]CD36030209 endocrinology & metabolismGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinebiology.animalparasitic diseasesInternal Medicinemedicine0303 health sciencesbiologyChemistryGeneral MedicineSmall intestineCell biologymedicine.anatomical_structurebiology.proteinlipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicine[SDV.AEN]Life Sciences [q-bio]/Food and NutritionChylomicronAtherosclerosis Supplements
researchProduct

Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs on the Small and Large Bowel

1999

Nonsteroidal anti-inflammatory drugs (NSAID) account for a large part of prescriptions and self-administered medication worldwide. The adverse effects on the upper gastrointestinal tract are well documented. However, in an increasing number of publications adverse effects in the small and large intestine distal to the duodenum are being reported. This paper provides an updated review of current as well as earlier literature on the pathogenesis of such adverse effects and the potential damage to the small and large bowel caused by NSAID. In addition, suggestions for an appropriate diagnostic workup of NSAID damage are discussed.

medicine.medical_specialtymedicine.drug_classBiopsydigestive systemGastroenterologyEndoscopy GastrointestinalAnti-inflammatorychemistry.chemical_compoundInternal medicineIntestine SmallmedicineHumansUpper gastrointestinalLarge intestineIntestine LargeIntestinal MucosaAdverse effectUlcerNonsteroidalbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologydigestive system diseasesSmall intestineIntestinal Diseasesmedicine.anatomical_structurechemistryDuodenumbusinessComplicationEndoscopy
researchProduct

Zespół przerostu bakteryjnego jelita cienkiego

2021

Zespół przerostu bakteryjnego jelita cienkiego (SIBO) jest heterogennym zespołem charakteryzującym się wzrostem liczby i/lub obecnością nietypowych bakterii w jelicie cienkim. Na złożoną etiologię SIBO składają się zaburzenia ochronnych mechanizmów przeciwbakteryjnych jak zmniejszona kwaśność soku żołądkowego, zewnątrzwydzielnicza niewydolność trzustki, zespoły niedoboru odporności oraz nieprawidłowości anatomiczne jak niedrożność jelita cienkiego, uchyłki, przetoki, hirurgiczna ślepa pętla, wcześniejsze resekcje krętniczo-kątnicze oraz zaburzenia ruchliwości. Objawy kliniczne SIBO mogą być niespecyficzne. Najczęściej występuje niestrawność, biegunka, wzdęcia, dyskomfort w jamie brzusznej. …

mikrobiotaSIBOIBSmicrobiotazespół przerostu bakteryjnego jelita cienkiegohydrogen breath testssmall intestine bacterial overgrowthwodorowe testy oddechowePostępy Mikrobiologii
researchProduct